Posted in | News | Chemical Sensor

Implant Sciences Announces Sale of 13 QS-B220 Desktop Explosives Trace Detectors to Second Belgium Airport

Implant Sciences Corporation, a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today announced that it has sold 13 of its QS-B220 desktop explosives trace detectors to a second airport in Belgium.

In a span of approximately two months, Implant Sciences has announced a number of major ETD sales to international airports in Europe, totaling up to 500 units across five countries.

"Implant Sciences has again been selected as the optimal vendor for ETDs in a competitive bidding process in the EU. Our strategy and execution has been nothing short of relentless, and our next-generation technology continues to be adopted by major customers" stated Dr. Darryl Jones, Vice President of Global Sales and Marketing for Implant Sciences. "The number of customer reference sites we have increases by the week, and going forward, we believe that our reputation for excellence will continue to propel us, not only in the aviation space, but in other verticals as well."

"We believe that, with every tender we are awarded, Implant Sciences is changing not only our company's trajectory, but also the shape of the ETD marketplace," added Dr. Bill McGann, Implant Sciences' CEO.  "Our success story is founded on the simple strategy of delivering the best technology to security operators, which is resulting in a growing wave of market victories.  We believe Implant Sciences' superior product offering and service are impacting the ETD landscape, and our satisfied customers are recognizing us as the emerging market leaders."

About the QS-B220 Desktop Explosives Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

Source: http://www.implantsciences.com

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Implant Sciences Corporation. (2019, February 24). Implant Sciences Announces Sale of 13 QS-B220 Desktop Explosives Trace Detectors to Second Belgium Airport. AZoSensors. Retrieved on April 18, 2024 from https://www.azosensors.com/news.aspx?newsID=9783.

  • MLA

    Implant Sciences Corporation. "Implant Sciences Announces Sale of 13 QS-B220 Desktop Explosives Trace Detectors to Second Belgium Airport". AZoSensors. 18 April 2024. <https://www.azosensors.com/news.aspx?newsID=9783>.

  • Chicago

    Implant Sciences Corporation. "Implant Sciences Announces Sale of 13 QS-B220 Desktop Explosives Trace Detectors to Second Belgium Airport". AZoSensors. https://www.azosensors.com/news.aspx?newsID=9783. (accessed April 18, 2024).

  • Harvard

    Implant Sciences Corporation. 2019. Implant Sciences Announces Sale of 13 QS-B220 Desktop Explosives Trace Detectors to Second Belgium Airport. AZoSensors, viewed 18 April 2024, https://www.azosensors.com/news.aspx?newsID=9783.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.